Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
      Google Scholar   
Citation:
Leuk Lymphoma vol 48 (7) 1313-9
Year:
2007
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
CA33601, CA77597, CA77658, K23 CA109004-01A1  
Corr. Author:
 
Authors:
             
Networks:
 
Study
CALGB-50206
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Adult, Boronic Acids, Bortezomib, Disease Progression, Female, Hodgkin Disease, Humans, Male, Middle Aged, Pyrazines, Salvage Therapy, Survival Analysis, Treatment Failure